pharma · Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis (PFIC) · MIRM
Mirum Pharmaceuticals International
Mirum Pharmaceuticals International B.V.
Mirum Pharmaceuticals International is a pharma organization headquartered in Foster City, USA. It trades on NYSE under ticker MIRM. Primary therapeutic focus areas include Alagille Syndrome, Progressive Familial Intrahe
989 E Hillsdale Blvd., Suite 300, Foster City, CA 94404, US HQ
2018 Founded
436 Employees
Public company Type
MIRM · NYSE Ticker
Company details
- Status
- Public
- HQ
- 989 E Hillsdale Blvd., Suite 300, Foster City, CA 94404, US
- Founded
- 2018
- Employees
- 436
- Programs
- 25
- Drugs
- 10
- Patents
- 4
LUM001 (Maralixibat)
Phase 2 · small molecule · Alagille Syndrome
LUM001 (Maralixibat) for Alagille Syndrome is a Phase 2 program (small_molecule) at Mirum Pharmaceuticals International B.V. with 3 ClinicalTrials.gov record(s).
Internal code LUM001-305
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mirum Pharmaceuticals International B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Alagille Syndrome
- Status
- completed
- Trials
- 3